Intracranial Metastatic Melanoma
Updated: 1 day ago
76 yo Male. Acute right side weakness • Xray of the Week

Figure 1. What is the diagnosis?

Figure 2.
A. T1 weighted image. Note the hyperintense nodules and masses with surrounding edema (red arrows). There is mass effect with narrowing of the left lateral ventricle and third ventricle, as well as rightward midline shift. B. T1 weighted image with contrast. Hyperintense nodules and masses with surrounding edema which also demonstrate contrast enhancement (yellow arrows) and large hemorrhagic lesion in left frontal lobe (green arrow) with hematocrit level compatible with hemorrhage. C. FLAIR image showing large hemorrhagic lesion in left frontal lobe with hematocrit level (green arrow).
Discussion:
Epidemiology Melanoma is the third most common source of brain metastasis overall, following lung and breast cancer. However, it carries the highest relative propensity among all primary systemic malignancies to metastasize to the central nervous system (CNS) [1,2]. Approximately 20% of patients with advanced metastatic melanoma will demonstrate intracranial involvement at the time of their initial diagnosis. Furthermore, as systemic disease progresses, greater than 50% of patients will eventually develop brain metastases [1,2]. The incidence of diagnosed brain metastases has grown in recent years, largely reflecting both improved neuroimaging techniques and prolonged patient survival due to advances in systemic therapies [2].
Clinical Findings Patients with intracranial metastatic melanoma frequently present with clinical symptoms indicative of elevated intracranial pressure, focal cortical irritation, or mass effect. Common presenting symptoms include persistent headaches, new-onset seizures, cognitive decline, or acute focal neurological deficits. In this case, a 76-year-old male presented with acute right-sided weakness. Melanoma brain metastases are characterized by profound tumor neovascularization and a direct tendency to invade regional blood vessels, making them highly susceptible to spontaneous hemorrhage. Consequently, many patients present acutely following a sudden intralesional hemorrhagic event, mimicking the presentation of a stroke.
Pathology Malignant melanoma is an aggressive neoplasm of melanocytes, which are specialized pigment-producing cells derived from the neural crest [1]. Based on their histopathologic melanin content, intracranial melanoma metastases can be broadly classified as either melanotic (containing greater than 10% melanin-containing cells) or amelanotic (containing fewer than 10% melanin-containing cells) [3].
The unique magnetic resonance (MR) signal characteristics of melanoma are driven largely by melanin and the presence of intralesional hemorrhage [3,4]. Melanin pigment possesses stable free radicals, such as semiquinones, which exert strong paramagnetic effects. These free radicals interact with surrounding protons to alter relaxation times. In addition, melanin acts as a natural chelating agent, binding paramagnetic metal ions such as iron, copper, and zinc [3-6]. The collective result of these paramagnetic interactions is a pronounced, intrinsic shortening of both T1 and T2 relaxation times [3-6].
Radiographic Features Magnetic resonance imaging (MRI) is the gold standard diagnostic modality for the initial evaluation and longitudinal follow-up of suspected intracranial metastatic disease. Most primary and metastatic intracranial tumors exhibit low signal intensity on T1-weighted images. However, melanotic melanoma uniquely demonstrates intrinsic high signal intensity on T1-weighted sequences and relative low signal intensity on T2-weighted sequences when compared to the normal cerebral cortex [3,5]. This distinctive signature is due to the aforementioned paramagnetic effects of melanin.
Conversely, amelanotic melanoma lacks sufficient melanin to inherently shorten the T1 relaxation time. In the absence of hemorrhage, amelanotic lesions behave much like typical brain metastases, demonstrating T1 isointensity or hypointensity and T2 hyperintensity [3].
However, neuroimaging interpretation is frequently complicated by the high incidence of intratumoral hemorrhage [4,5]. As seen in the provided case, the presence of subacute hemorrhage results in the accumulation of methemoglobin. Because methemoglobin is also strongly paramagnetic, it inherently shortens T1 relaxation times, producing prominent T1 hyperintensity regardless of the underlying melanin concentration [4-7]. Thus, a purely amelanotic metastasis may still appear diffusely T1 hyperintense if there has been a recent bleed.
In the provided case images, there are multiple intra-axial nodules and masses demonstrating intrinsic T1 hyperintensity with abundant surrounding vasogenic edema. Following the administration of gadolinium-based contrast, these lesions exhibit robust enhancement, which can present in a nodular, ring-like, or heterogeneous pattern (Figs. 1-2 ). A prominent, large mass in the left frontal lobe demonstrates a hematocrit fluid-fluid level on the FLAIR and contrast-enhanced images, which is a hallmark radiologic sign of intralesional hemorrhage. The resultant mass effect causes narrowing of the left lateral and third ventricles alongside a rightward midline shift (Figs. 1-2 ).
On non-contrast computed tomography (CT), melanoma metastases are often hyperdense relative to the adjacent cortex. This hyperattenuation can be attributed to high cellularity, dense melanin content, or the presence of acute blood products. Susceptibility-weighted imaging (SWI) or T2* gradient-echo sequences are exquisitely sensitive for melanoma, typically revealing profound signal dropout or blooming artifact due to the dense concentration of paramagnetic melanin and blood degradation products [4].
Treatment and Prognosis Historically, the prognosis for patients with intracranial metastatic melanoma was exceptionally grim, with a median overall survival of less than six months [2]. However, the treatment paradigm has shifted radically in the modern era with the advent of targeted therapies (such as BRAF and MEK inhibitors for patients harboring BRAF V600 mutations) and immune checkpoint inhibitors (such as anti-PD-1 and anti-CTLA-4 antibodies) [2].
Current management requires a tailored, multidisciplinary approach. For patients presenting with large, highly symptomatic lesions causing significant mass effect or impending herniation (such as the large hemorrhagic left frontal mass seen in this patient), prompt surgical resection is often pursued to relieve intracranial pressure and stabilize the patient [7-10]. For patients with a limited number of smaller, asymptomatic metastases, stereotactic radiosurgery (SRS) has largely replaced whole-brain radiation therapy (WBRT). SRS offers excellent local control while limiting radiation-induced neurocognitive decline. The integration of localized SRS with modern systemic immunotherapy has synergistically improved outcomes, leading to durable intracranial responses and extending overall survival from months to several years for many patients [2].
Conclusion
Intracranial metastatic melanoma is a clinically devastating manifestation of advanced disease that frequently presents with spontaneous intralesional hemorrhage. The distinctive radiologic signature of these lesions—specifically, intrinsic T1 hyperintensity and T2 hypointensity—is driven by the potent paramagnetic properties of melanin or concurrent subacute hemorrhage. Familiarity with these characteristic imaging features and their pathophysiological basis is essential for radiologists to accurately narrow the differential diagnosis and optimally guide multidisciplinary neuro-oncologic management..
References:
Patnana M, et al. Multimethod Imaging, Staging, and Spectrum of Manifestations of Metastatic Melanoma. Clinical Radiology, vol. 66, no. 3, Mar. 2011, pp. 224–36. doi:10.1016/j.crad.2010.10.014 PubMed: https://pubmed.ncbi.nlm.nih.gov/21295201/
Vosoughi Elham, et al. Survival and Clinical Outcomes of Patients with Melanoma Brain Metastasis in the Era of Checkpoint Inhibitors and Targeted Therapies. BMC Cancer, vol. 18, no. 1, Apr. 2018, p. 490. BioMed Central, doi:10.1186/s12885-018-4374-x PubMed: https://pubmed.ncbi.nlm.nih.gov/29703180/
Isiklar I, et al. Intracranial Metastatic Melanoma: Correlation between MR Imaging Characteristics and Melanin Content. American Journal of Roentgenology, vol. 165, no. 6, Dec. 1995, pp. 1503–12. doi:10.2214/ajr.165.6.7484597 PubMed: https://pubmed.ncbi.nlm.nih.gov/7484597/
Cakirer S, et al. Spontaneously T1-Hyperintense Lesions of the Brain on MRI: A Pictorial Review. Current Problems in Diagnostic Radiology, vol. 32, no. 5, Oct. 2003, pp. 194–217. doi:10.1016/s0363-0188(03)00026-4 PubMed: https://pubmed.ncbi.nlm.nih.gov/12963867/
Zimny A, et al. Intracranial Lesions with High Signal Intensity on T1-Weighted MR Images – Review of Pathologies. Polish Journal of Radiology, vol. 78, no. 4, 2013, pp. 36–46. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908506/
Ma, Mian, et al. Neurocutaneous Melanosis in an Adult Patient with Intracranial Primary Malignant Melanoma: Case Report and Review of the Literature. World Neurosurgery, vol. 114, June 2018, pp. 76–83. ScienceDirect. doi:10.1016/j.wneu.2018.02.007
Goulart CR, et al. Cerebral Melanoma Metastases: A Critical Review on Diagnostic Methods and Therapeutic Options. ISRN Surgery, vol. 2011, 2011. doi:10.5402/2011/276908
Ma YF, et al. Intracranial Malignant Melanoma: A Report of 7 Cases. Oncology Letters, vol. 10, no. 4, Oct. 2015, pp. 2171–75. PubMed Central, doi:10.3892/ol.2015.3537
Goyal S, et al. The Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncology, vol. 1, no. 5, Aug. 2015, pp. 668–76. doi:10.1001/jamaoncol.2015.1206
Ginat DT, Meyers SP. Intracranial Lesions with High Signal Intensity on T1-weighted MR Images: Differential Diagnosis. RadioGraphics. 2012;32(2):499-516. doi:10.1148/rg.322105761. PubMed: https://pubmed.ncbi.nlm.nih.gov/22411945/

Updated: 08/25/2024: Amara Ahmed is a Radiology Resident at The University of Florida. https://residency.xray.ufl.edu/residents/class-of-2028/
She did her medical school at the Florida State University College of Medicine. She serves on the executive board of the American Medical Women’s Association and Humanities and Medicine. She is also an editor of HEAL: Humanism Evolving through Arts and Literature, a creative arts journal at the medical school. Prior to attending medical school, she graduated summa cum laude from the Honors Medical Scholars program at Florida State University where she completed her undergraduate studies in exercise physiology, biology, and chemistry. In her free time, she enjoys reading, writing, and spending time with family and friends.
Follow Amara Ahmed on Twitter @Amara_S98

Kevin M. Rice, MD is the president of Global Radiology CME
Dr. Rice is a radiologist with Renaissance Imaging Medical Associates and is currently the Vice Chief of Staff at Valley Presbyterian Hospital in Los Angeles, California. Dr. Rice has made several media appearances as part of his ongoing commitment to public education. Dr. Rice's passion for state of the art radiology and teaching includes acting as a guest lecturer at UCLA. In 2015, Dr. Rice and Natalie Rice founded Global Radiology CME to provide innovative radiology education at exciting international destinations, with the world's foremost authorities in their field. In 2016, Dr. Rice was nominated and became a semifinalist for a "Minnie" Award for the Most Effective Radiology Educator.
Follow Dr. Rice on Twitter @KevinRiceMD



















Comments